Dublin, Ireland-based Endo International plc (NASDAQ:ENDP) is a specialty pharmaceutical company focused on branded and generic pharmaceuticals products as well as over-the-counter medications through its operating companies. The company has several products including Lidoderm, Opana ER, Supprelin LA and Fortesta Gel in its Branded Pharmaceuticals portfolio.
Endo has implemented a growth-by-acquisition strategy. The company has acquired privately held Par Pharmaceutical, which boosted its generics portfolio and pipeline. The company also acquired a broad portfolio of branded and generic injectable and established products focused on pain, anti-infectives, cardiovascular and other specialty therapeutics areas from a subsidiary of Aspen Holdings.
Endo has been consistently beating earnings expectations. In fact, Endo posted a positive surprise in each of the trailing four quarters, with an average positive surprise of 12.7%.
Currently, Endo has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Endo surpassed first-quarter 2017 earnings. The company reported EPS of $1.23 while our consensus called for EPS of $1.12.
Revenues: Revenues were in line with expectations. Endo posted revenues of $1.03 billion in line with the consensus estimate.
Key Stats: Revenues were up on a year over year basis due to the launch of key first-to-file generic products for Seroquel and Zetia.
2017 Guidance: Endo expects revenues in the range of $3.45 billion to $3.60 billion. The company expects earnings from continuing operations in the range of $3.45 to $3.75 per share. The Zacks Consensus Estimate for earnings is $3.63 per share on revenues of $3.55 billion.
Pre-Market Trading: Shares did not show any movement in the pre-market trading.
Check back later for our full write up on this ENDP earnings report later!
Endo International PLC Price and EPS Surprise
Endo International PLC Price and EPS Surprise | Endo International PLC Quote
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time. One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>
Endo International PLC (ENDP): Free Stock Analysis Report
Original post